MX2016014615A - Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes. - Google Patents

Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.

Info

Publication number
MX2016014615A
MX2016014615A MX2016014615A MX2016014615A MX2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A
Authority
MX
Mexico
Prior art keywords
imaging agents
heterocyclic compounds
salts
compounds
deuterated
Prior art date
Application number
MX2016014615A
Other languages
English (en)
Inventor
P Lyssikatos Joseph
Marik Jan
Williams Simon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016014615A publication Critical patent/MX2016014615A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos deuterados y etiquetados detectables opcionalmente de la fórmula (I): R1-A-R2 y de la fórmula (V) y las sales de los mismos, en donde R1, R2, A y X10-X19 tienen cualquiera de los valores definidos en la especificación. También se incluyen las composiciones farmacéuticas que comprenden tales compuestos y las sales, y los métodos de uso de tales compuestos y las sales como agentes formadores de imágenes, en particular en la medición de la señal radioactiva del compuesto asociado con los depósitos amiloides y/o los agregados de la proteína tau.
MX2016014615A 2014-05-13 2015-05-12 Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes. MX2016014615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (1)

Publication Number Publication Date
MX2016014615A true MX2016014615A (es) 2017-03-06

Family

ID=53269446

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014615A MX2016014615A (es) 2014-05-13 2015-05-12 Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
MX2020010847A MX2020010847A (es) 2014-05-13 2015-05-12 Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010847A MX2020010847A (es) 2014-05-13 2015-05-12 Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.

Country Status (21)

Country Link
US (4) US10076581B2 (es)
EP (2) EP3901145A1 (es)
JP (2) JP6529986B2 (es)
KR (2) KR102618139B1 (es)
CN (2) CN110483522B (es)
AU (2) AU2015261008B2 (es)
CA (1) CA2948721C (es)
DK (1) DK3143011T3 (es)
ES (1) ES2867814T3 (es)
HR (1) HRP20210641T1 (es)
HU (1) HUE053939T2 (es)
IL (3) IL280791B2 (es)
LT (1) LT3143011T (es)
MX (2) MX2016014615A (es)
PL (1) PL3143011T3 (es)
PT (1) PT3143011T (es)
RS (1) RS61810B1 (es)
RU (1) RU2696492C2 (es)
SG (2) SG11201609281UA (es)
SI (1) SI3143011T1 (es)
WO (1) WO2015173225A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016014615A (es) 2014-05-13 2017-03-06 Hoffmann La Roche Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
SG11201811311VA (en) 2016-07-22 2019-01-30 Ac Immune Sa Compounds for imaging tau protein aggregates
IL290809B2 (en) * 2016-11-01 2024-01-01 Arvinas Operations Inc PROTACS Targeted Tau-Protein and Related Methods of Use
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
US20210041447A1 (en) 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
EP3758696A4 (en) 2018-03-02 2021-12-08 The Trustees of the University of Pennsylvania [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AND USE OF THESE IN THE STABILIZATION OF MICROTUBULES
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
MX2021003158A (es) 2018-09-18 2021-07-16 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
DK3860989T3 (da) 2018-10-05 2023-05-01 Forma Therapeutics Inc Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30)
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
JP7369208B2 (ja) * 2019-05-09 2023-10-25 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 標識されたイミダゾ[1,2-a]ピリミジンの合成
JP2022540935A (ja) 2019-07-17 2022-09-20 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
TW202328177A (zh) 2021-08-27 2023-07-16 美商建南德克公司 治療tau病理學之方法
WO2023245008A1 (en) 2022-06-13 2023-12-21 Genentech, Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD76515A (es) *
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
SI1999109T1 (sl) 2006-03-30 2012-04-30 Univ Pennsylvania Derivati stirilpiridina in njihova uporaba za vezavo in prikazovanje amiloidnih plakov
EP2200997B9 (en) * 2007-09-13 2016-01-13 Concert Pharmaceuticals Inc. Synthesis of deuterated benzodioxoles
US8318132B2 (en) 2008-02-14 2012-11-27 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
EP2450332A1 (en) 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
AU2011331301A1 (en) * 2010-11-15 2013-05-23 Katholieke Universiteit Leuven Antiviral condensed heterocyclic compounds
CA2873963C (en) * 2012-05-22 2017-04-11 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
PE20160159A1 (es) * 2013-10-08 2016-03-18 Hoffmann La Roche Derivados de diazacarbazol como ligandos de tau para pet
MX2016014615A (es) 2014-05-13 2017-03-06 Hoffmann La Roche Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.

Also Published As

Publication number Publication date
EP3143011A1 (en) 2017-03-22
IL271631A (en) 2020-02-27
KR20170002639A (ko) 2017-01-06
CA2948721C (en) 2023-03-28
RU2016147742A3 (es) 2018-10-08
US20160250358A1 (en) 2016-09-01
EP3901145A1 (en) 2021-10-27
KR102618139B1 (ko) 2023-12-27
WO2015173225A1 (en) 2015-11-19
KR20230035445A (ko) 2023-03-13
US10675367B2 (en) 2020-06-09
NZ726208A (en) 2023-11-24
IL271631B (en) 2021-05-31
JP2019147825A (ja) 2019-09-05
US20190201561A1 (en) 2019-07-04
PT3143011T (pt) 2021-04-26
RS61810B1 (sr) 2021-06-30
PL3143011T3 (pl) 2021-07-19
ES2867814T3 (es) 2021-10-20
IL280791B2 (en) 2024-03-01
MX2020010847A (es) 2021-07-16
US11504440B2 (en) 2022-11-22
CN110483522B (zh) 2022-05-03
CN110483522A (zh) 2019-11-22
DK3143011T3 (da) 2021-05-03
IL248692A0 (en) 2017-01-31
IL248692B (en) 2020-01-30
KR102530129B1 (ko) 2023-05-10
HRP20210641T1 (hr) 2021-05-28
AU2015261008B2 (en) 2019-02-14
IL280791B1 (en) 2023-11-01
BR112016026443A2 (pt) 2017-08-15
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
HUE053939T2 (hu) 2021-08-30
US20230218782A1 (en) 2023-07-13
JP6681498B2 (ja) 2020-04-15
EP3143011B1 (en) 2021-03-03
JP2017515856A (ja) 2017-06-15
AU2019203369A1 (en) 2019-06-06
RU2016147742A (ru) 2018-06-18
NZ764181A (en) 2023-11-24
US10076581B2 (en) 2018-09-18
CA2948721A1 (en) 2015-11-19
AU2015261008A1 (en) 2016-11-17
BR112016026443A8 (pt) 2021-07-06
JP6529986B2 (ja) 2019-06-12
SG11201609281UA (en) 2016-12-29
CN106459059A (zh) 2017-02-22
CN106459059B (zh) 2019-09-24
LT3143011T (lt) 2021-05-10
SI3143011T1 (sl) 2021-08-31
US20200297875A1 (en) 2020-09-24
IL280791A (en) 2021-04-29
AU2019203369B2 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
MX2016014615A (es) Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
MY191590A (en) 9h-pyrrolo-dipyridine derivatives
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
GEP20196942B (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
CY1120535T1 (el) Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
BR112017020046A2 (pt) composto cristalino como inibidor de enzima amina oxidase sensível à semicarbazida (ssao)
WO2015102024A3 (en) Novel substituted 5 membered heterocyclic compounds and preparation thereof
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
EA201690908A1 (ru) Пиразолопиримидиновые соединения
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.

Legal Events

Date Code Title Description
FG Grant or registration